Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 56Terminated 8Withdrawn 3Unknown 3Recruiting 2Not yet recruiting 2Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Breast Neoplasms 11Lymphoma, Large B-Cell, Diffuse 10Triple Negative Breast Neoplasms 8Recurrence 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, B-Cell 6Neoplasm Metastasis 4Multiple Myeloma 4Leukemia, Myeloid, Acute 4Leukemia 4Neuroblastoma 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma 3Hematologic Neoplasms 3Head and Neck Neoplasms 3Graft vs Host Disease 3Squamous Cell Carcinoma of Head and Neck 2Oropharyngeal Neoplasms 2Neoplasms, Plasma Cell 2Lymphoma, Follicular 2Hodgkin Disease 2Dendritic Cell Sarcoma, Interdigitating 2Carcinoma, Renal Cell 2Brain Neoplasms 2Wilms Tumor 1Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1

Interventions

polatuzumab vedotin 2glofitamab 2Prednisone 2Doxorubicin 2Cyclophosphamide 2relmacabtagene autoleucel 1obinutuzumab 1axicabtagene ciloleucel 1Rituximab 1Oxaliplatin 1Gemcitabine 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Dendritic Cell Sarcoma, Interdigitating × Cyclophosphamide × Clear all
NCT07231250 2025-11-19

Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

Sun Yat-sen University

Phase 2 Not yet recruiting
40 enrolled
Sarcoma

Dendritic Cell Sarcoma, Interdigitating

NCT07034508 2025-06-24

A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Not yet recruiting
134 enrolled
Sarcoma

Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡